Prevalence and Impact of Vaginal Symptoms among Postmenopausal Women

被引:247
作者
Santoro, Nanette [1 ]
Komi, Janne [2 ]
机构
[1] Albert Einstein Coll Med, Div Reprod Endocrinol, New York, NY 10461 USA
[2] QuatRx Pharmaceut Co, Ann Arbor, MI USA
关键词
Vulvoaginal Atrophy; Menopause; Menopausal Hormone Therapy; Sexual Activity; Vagina; Vaginal Symptoms; CARDIOVASCULAR-DISEASE; VASOMOTOR SYMPTOMS; HORMONE-THERAPY; SEXUAL FUNCTION; ESTROGEN; HEALTH; MENOPAUSE; ATROPHY; RISK;
D O I
10.1111/j.1743-6109.2009.01335.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. Vulvovaginal atrophy (VVA) is reported by one-quarter to one-half of postmenopausal women. Aim. We evaluated the prevalence, inconvenience of, and issues surrounding hormone use for VVA symptoms in women who were current, past, and never users of menopausal hormone therapy (MHT), along with the relationship of sexual activity to VVA symptoms. Methods. An online survey was sent to 3,471 women >= 45 years old participating in a panel of approximately 43,000 U.S. adults maintained by Knowledge Networks. Respondents were stratified by MHT use (current, past, and never) and sexual activity (sexually active and not sexually active). Final respondent data underwent a poststratification process and Chi-square analysis of hormone use and VVA by sexual activity. Main Outcome Measures. Percent, calculated as the ratio of response over total responding for each survey question for all and stratified respondents. Results. Forty-five percent (1,038/2,290) of respondents (age range 45-89 years; mean 60.7 years) were postmenopausal and currently or previously experienced VVA. Approximately 60% of past or never users of MHT reported vaginal symptoms; > 90% found them bothersome. In comparison, 82% of current users reported VVA symptoms prior to use. 85% of all respondents were aware of safety issues associated with MHT. The prevalence and perceived severity of VVA symptoms were substantial but less frequent in nonsexually active women. Analysis of MHT use by past or current hormone use indicated a trend away from oral dosing and towards patch or vaginal hormones. Conclusions. Postmenopausal women have a high rate of VVA symptoms. Those who use MHT do so for multiple reasons-hot flashes, VVA, bone protection, dyspareunia-and most have concerns about long-term safety, despite the fact that the majority of MHT use was for > 5 years. Safety concerns and lack of physician recommendation were major reasons for not using or discontinuing MHT. Santoro N, and Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133-2142.
引用
收藏
页码:2133 / 2142
页数:10
相关论文
共 25 条
[1]   Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[2]  
BACHMANN GA, 2008, END SOC ANN M SAN FR
[3]  
Carroll DG, 2006, AM FAM PHYSICIAN, V73, P457
[4]   Comparison of the effects of hormone therapy regimens, oral and vaginal estradiol, estradiol plus drospirenone and tibolone, on sexual function in healthy postmenopausal women [J].
Cayan, Filiz ;
Dilek, Umut ;
Pata, Oezlem ;
Dilek, Saffet .
JOURNAL OF SEXUAL MEDICINE, 2008, 5 (01) :132-138
[5]   Non-hormonal therapy of post-menopausal vasomotor symptoms: A structured evidence-based review [J].
Cheema D. ;
Coomarasamy A. ;
El-Toukhy T. .
Archives of Gynecology and Obstetrics, 2007, 276 (5) :463-469
[6]   THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST-CANCER IN POSTMENOPAUSAL WOMEN [J].
COLDITZ, GA ;
HANKINSON, SE ;
HUNTER, DJ ;
WILLETT, WC ;
MANSON, JE ;
STAMPFER, MJ ;
HENNEKENS, C ;
ROSNER, B ;
SPEIZER, FE .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (24) :1589-1593
[7]   Sexual function in well women: Stratification by sexual satisfaction, hormone use, and menopause status [J].
Davison, Sonia L. ;
Bell, Robin J. ;
LaChina, Maria ;
Holden, Samantha L. ;
Davis, Susan R. .
JOURNAL OF SEXUAL MEDICINE, 2008, 5 (05) :1214-1222
[8]   A prospective population-based study of menopausal symptoms [J].
Dennerstein, L ;
Dudley, EC ;
Hopper, JL ;
Guthrie, JR ;
Burger, HG .
OBSTETRICS AND GYNECOLOGY, 2000, 96 (03) :351-358
[9]  
Freedman M, 2007, MENOPAUSE, V14, P1107
[10]   KEEPS: The Kronos Early Estrogen Prevention Study [J].
Harman, SM ;
Brinton, EA ;
Cedars, M ;
Lobo, R ;
Manson, JE ;
Merriam, GR ;
Miller, VM ;
Naftolin, F ;
Santoro, N .
CLIMACTERIC, 2005, 8 (01) :3-12